Tage Honoré

Dr. Tage Honoré has been appointed as the Company’s Chairman of the Scientific Advisory Board.

Dr. Honoré is an experienced pharma and biotechnology executive, entrepreneur and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis, anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy, learning disorders, osteoporosis, Parkinson’s disease, stroke and schizophrenia. His greatest scientific achievement was discovering and naming the AMPA subtype of Excitatory Amino Acid Receptors as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system.